TABLE 1.
Demographic and Clinical Characteristics of Study Patients
| Baseline Characteristics | Escitalopram, n = 26 | Placebo, n = 25 |
|---|---|---|
| Age, years | 14.8±1.7 | 14.9±1.6 |
| Female, n (%) | 20 (77) | 19 (76) |
| Duke Tanner Stage, n (%) | ||
| Stage 3, female ∣ male | 6 (23) ∣ 3 (12) | 1 (4) ∣ 0 (0) |
| Stage 4, female ∣ male | 5 (19) ∣ 3 (12) | 10 (40) ∣ 5 (20) |
| Stage 5, female ∣ male | 9 (34) ∣ 0 (0) | 8 (32) ∣ 1 (4) |
| Race, n (%) | ||
| Asian | 0 (0) | 2 (8) |
| Black and African American | 1 (4) | 1 (4) |
| Caucasian | 23 (88) | 20 (80) |
| Other | 2 (8) | 2 (8) |
| Hispanic or Latino | 3 (12) | 0 (0) |
| Full scale IQ | 106±12 | 105±10 |
| PARS score | 18±2 | 17±2 |
| CGI-Severity score, median | 4 | 4 |
| CDRS-R score, mean | 33±4 | 32±6 |
| PSC score, mean | 23.12±3.15 | 30.76±4.99 |
| Co-occurring disorders, n (%) | ||
| Separation anxiety | 4 (15) | 5 (20) |
| Panic disorder | 13 (50) | 15 (60) |
| Agoraphobia | 7 (27) | 7 (28) |
| ADHD | 5 (19) | 4 (16) |
| Specific phobia | 9 (35) | 3 (12) |
| Prior SSRI/SNRI treatment, n (%) | 6 (23) | 7 (28) |
| Current psychotherapy treatment, n (%) | 3 (6) | 5 (10) |
| CYP2C19 genotype | ||
| *2/*2 | 1 (4) | |
| *1/*2 | 5 (19) | |
| *1/*1 | 10 (38) | |
| *1/*17 | 4 (15) | |
| *2/*17 | 3 (12) | |
| *4/*17 | 2 (8) 1 (4) |
|
| *17/*17 | 1 (4) | |
CGI-S, Clinical Global Impression Scale-Severity; CGI-I, Clinical Global Impression Scale-Improvement; CDRS-R, Children’s Depression Rating Scale-Revised; PARS, Pediatric Anxiety Rating Scale; ADHD, Attention/Deficit-Hyperactivity Disorder; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; PSC, Physical Symptom Checklist.